Literature DB >> 32607077

Clinically Assessed Walking Capacity Versus Real-World Walking Performance in People with Multiple Sclerosis.

Kedar K V Mate, Nancy E Mayo.   

Abstract

BACKGROUND: Ecological validity is an important psychometric property when assessing function. How a person with multiple sclerosis (MS) performs in clinical settings and in natural environments can be quite different. Walking is the most frequently assessed and recommended way to maintain health in a progressive disease such as MS. The objective was to estimate the extent to which clinical tests of walking capacity differ from real-world walking performance in people with MS.
METHODS: Ninety-eight women and 27 men with MS were assessed using the 6-Minute Walk Test (6MWT) and wore an accelerometer for 7 consecutive days. Mean number of steps, mean number of steps at a brisk cadence or faster, and cumulative time per week spent walking at a brisk cadence or faster were regressed on 6MWT categories using quantile (median) regression. Contiguous steps were grouped into bouts of less than 5 minutes and 5 minutes or longer, and number of bouts 5 minutes or longer was regressed on 6MWT categories using a zero-inflated Poisson model.
RESULTS: A total of 869 patient-days of accelerometer data were available. Mean total number of steps per day was greater for people with higher walking capacity (6MWT distance, ≥600 m). However, this group spent a small proportion of time walking at higher cadence bands. Compared with people with 6MWT distance of at least 600 m, people walking less than 500 m had approximately half the rate of walking bouts of 5 minutes or longer. Positive mood and fewer exercise barriers predicted more walking bouts of at least 5 minutes.
CONCLUSIONS: Study participants with MS spent a small proportion of time walking at a health-promoting intensity.
© 2020 Consortium of Multiple Sclerosis Centers.

Entities:  

Keywords:  Ecological validity; Multiple sclerosis (MS); Six-Minute Walk Test; Walking capacity; Walking performance

Year:  2020        PMID: 32607077      PMCID: PMC7307876          DOI: 10.7224/1537-2073.2019-047

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  30 in total

1.  Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls.

Authors:  Myla D Goldman; Ruth Ann Marrie; Jeffrey A Cohen
Journal:  Mult Scler       Date:  2007-10-17       Impact factor: 6.312

Review 2.  Health benefits of physical activity: the evidence.

Authors:  Darren E R Warburton; Crystal Whitney Nicol; Shannon S D Bredin
Journal:  CMAJ       Date:  2006-03-14       Impact factor: 8.262

3.  Patterns of adult stepping cadence in the 2005-2006 NHANES.

Authors:  Catrine Tudor-Locke; Sarah M Camhi; Claudia Leonardi; William D Johnson; Peter T Katzmarzyk; Conrad P Earnest; Timothy S Church
Journal:  Prev Med       Date:  2011-06-25       Impact factor: 4.018

Review 4.  Commercially available accelerometry as an ecologically valid measure of ambulation in individuals with multiple sclerosis.

Authors:  Robert W Motl; Brian M Sandroff; Jacob J Sosnoff
Journal:  Expert Rev Neurother       Date:  2012-09       Impact factor: 4.618

5.  Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants.

Authors:  R W Bohannon
Journal:  Age Ageing       Date:  1997-01       Impact factor: 10.668

6.  Residents of highly walkable neighbourhoods in Canadian urban areas do substantially more physical activity: a cross-sectional analysis.

Authors:  Justin Thielman; Heather Manson; Maria Chiu; Ray Copes; Laura C Rosella
Journal:  CMAJ Open       Date:  2016-12-01

Review 7.  The behaviour change wheel: a new method for characterising and designing behaviour change interventions.

Authors:  Susan Michie; Maartje M van Stralen; Robert West
Journal:  Implement Sci       Date:  2011-04-23       Impact factor: 7.327

8.  Ecological validity of walking capacity tests in multiple sclerosis.

Authors:  J P Stellmann; A Neuhaus; N Götze; S Briken; C Lederer; M Schimpl; C Heesen; M Daumer
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

9.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

Review 10.  What interventions are used to improve exercise adherence in older people and what behavioural techniques are they based on? A systematic review.

Authors:  Jonathan Room; Erin Hannink; Helen Dawes; Karen Barker
Journal:  BMJ Open       Date:  2017-12-14       Impact factor: 2.692

View more
  2 in total

1.  Making Every Step Count: Minute-by-Minute Characterization of Step Counts Augments Remote Activity Monitoring in People With Multiple Sclerosis.

Authors:  Valerie J Block; Matthew Waliman; Zhendong Xie; Amit Akula; Riley Bove; Mark J Pletcher; Gregory M Marcus; Jeffrey E Olgin; Bruce A C Cree; Jeffrey M Gelfand; Roland G Henry
Journal:  Front Neurol       Date:  2022-05-23       Impact factor: 4.086

2.  Agreement, Reliability, and Concurrent Validity of an Outdoor, Wearable-Based Walk Ratio Assessment in Healthy Adults and Chronic Stroke Survivors.

Authors:  Simone K Huber; Ruud H Knols; Jeremia P O Held; Tom Christen; Eling D de Bruin
Journal:  Front Physiol       Date:  2022-06-20       Impact factor: 4.755

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.